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Summary 
The role of interleukin 6 (IL-6) in the toxic sequelae of sepsis is controversial.  To assess the part 
of IL-6 in inflammatory responses to endotoxin, we investigated eight chimpanzees after either 
a bolus intravenous injection of Escherichia coli endotoxin (n  --  4; 4 ng/kg) or after the same 
dose of endotoxin with a simultaneous bolus intravenous injection of an anti-IL-6 mAb (30 mg; 
n  =  4). Anti-IL-6 did not affect the induction of the cytokine network (tumor necrosis factor 
[TNF], soluble TNF receptors types I and II, and IL-8) by endotoxin, nor did it influence the 
occurrence of a neutrophilic leukocytosis and neutrophil degranulation, as monitored by the 
measurement of elastase-oll-antitrypsin  complexes.  In contrast, anti-IL-6 markedly attenuated 
endotoxin-induced  activation of coagulation, monitored with the plasma levels of the prothrombin 
fragment FI+ 2 and thrombin-antithrombin III complexes,  whereas activation of fibrinolysis, 
determined with the plasma concentrations of plasmin-c~2-antiplasmin  complexes,  remained 
unaltered. We conclude that IL-6 does not have a feedback effect on the release of other cytokines 
after injection of endotoxin, and that it is not involved in endotoxin-induced neutrophilia or 
neutrophil degranulation. IL-6 is, however,  an important intermediate factor in activation of 
coagulation in low grade endotoxemia in chimpanzees. 
I 
L-6 is a pleiotropic cytokine that exerts multiple effects on 
. many different types of target cells. Major biologic activi- 
ties of IL-6 include induction of acute phase protein synthesis 
in hepatocytes,  induction of the terminal differentiation of 
B cells, and activation ofT cells (1). 11,-6  is one of the cytokines 
that is released early in the course of systemic infection. In 
experimental lethal bacteremia in baboons, the appearance 
of IL-6 in the circulation shortly follows that of TNF (2). 
In addition, elevated serum concentrations of IL-6 are found 
in the majority of patients with sepsis and show a strong 
positive correlation with mortality rates (3, 4). It is uncer- 
tain, however, to what extent IL-6 is involved in tissue in- 
jury in sepsis. Passive immunization against IL-6 confers only 
limited protection against lethality induced by endotoxin in 
mice (5, 6), and administration of high doses of recombinant 
IL-6 does not cause hypotension or endothelial damage in 
laboratory animals (7). The induction of IL-6 synthesis may 
even serve to protect the host against the destructive poten- 
tial of more toxic members of the cytokine cascade, since in 
vitro IL-6 suppresses endotoxin-induced  production of TNF 
and IL-1 (8, 9). This study aimed to more spedfically inves- 
tigate the intermediate role of IL-6 in inflammatory responses 
known to contribute to organ damage in sepsis. For this pur- 
pose, chimpanzees were intravenously injected with a bolus 
dose of endotoxin with or without a neutralizing anti-IL-6 
mAb, and sequential measurements were performed to mon- 
itor cytokine release, neutrophil activation, and activation of 
the coagulation and fibrinolytic systems. 
Materials  and Methods 
Study Design.  Eight healthy  adult chimpanzees  (Pan troglodytes) 
were studied. They were recruited from the Laboratory for Ex- 
perimental  Medicine  and Surgery  in Primates (LEMSIP) (New York 
University School of Medicine, New York). None of the animals 
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panzees were sedated  with ketamin chloride, and after intubation, 
kept under general anesthesia with nitrous oxide and halothane 
until the end of the 5-h experiment. Vital functions were regis- 
tered during the entire experiment. All chimpanzees  received  a bolus 
intravenous injection of purified endotoxin (lot EC-5 from Esche. 
richia coli 0113, Federal  Drug Administration standard preparation) 
at a dose of 4 ng/kg body weight. Four animals also received a 
bolus intravenous injection of 30 mg anti-II,6 mAb immediately 
before the administration of endotoxin. Anti-IL-6 mAb CLB.IL, 
6/#8 is a murine IgG1 against human IL,6  that potently neutralizes 
IL-6 activity in biological assays (Ka 6  x  10-12 M) (10). CLB.IL 
6/#8 does not discriminate between human and chimpanzee Ib6. 
The antibodies were produced by in vitro cultures and purified by 
protein A-Sepharose chromatography (10). The dose of  endotoxin 
chosen has been shown to induce reproducible systemic  inflamma- 
tory responses (11). Clinical signs, including fever, are minimal or 
absent. Control studies, i.e., without injection of endotoxin, have 
demonstrated that the experimental procedures themselves  do not 
elicit changes in the inflammatory parameters under investigation 
(11). Venous blood samples were obtained by separate venipunc- 
tures directly before the administration of endotoxin and at 0.5, 
1, 1.5, 2, 3, 4, and 5 h thereafter. All blood samples (except samples 
for determination of  leukocyte  and phtelet counts) were centrifuged 
at 4~  for 20 rain at 1,600 g and stored at  -70~  until assays 
were performed. The protocol was approved by the animal health 
and welfare committees of LEMSIP and was conducted according 
to the guidelines of the American Physiological  Society. 
Assays.  Serum  levels  ofCLB,  ID6/#8 were determined  by ELISA 
using recombinant human IL-6  as capturing agent and peroxidase- 
conjugated rat mAb against mouse g L chain as detecting agent. 
Serum IL-6 concentrations were measured with ELISA (12) and 
with the B9 bioassay (13). The capture antibody in the ELISA is 
mAb CLB.IL-6/#16.  Binding of  IL-6 to this antibody is not affected 
by the presence of as much as 10/~g/ml of CLB.IL-6/#8 because 
these antibodies  recognize  independent  epitopes (10). However,  there 
is some interference with the polyclonal second antibodies used 
in the ELISA (data not shown), leading to a slight underestima- 
tion of IL-6 levels. The B9 assay is disturbed by the presence of 
excessive amounts of CLB.IL-6/#8. However, we have shown pre- 
viously  that another mAb to Ib6 (CLB.IL-6/#14)  can compete with 
mAb CLB.IL-6/#8  for Ib-6 binding (10). As CLB.IL-6/#14  is non- 
neutralizing, addition of an excess (10/zg/ml)  of CLB/II,6/#14 
to the B9 assay allows quantitation of IL6, even in the presence 
ofmAb CLB.IL-6/#8  (14). TNF serum levels were determined with 
an immuno radiometric assay (IRMA) (Medgenix, Fleurus, Bel- 
gium). The serum concentrations of the type I and II soluble 
receptors for TNF (sTNFR  1 type I and type II) were measured 
with enzyme-bound immunological assays (Hoffmann La Roche 
Ltd., Basel, Switzerland) (15, 16). II--8 serum levels were deter- 
mined with an ELISA (17). Leukocyte and platelet counts were 
determined in blood anticoagtilated with 0.38 mM EDTA using 
flow  cytometry.  Blood for  the  measurement of  ehstase-c~l- 
antitrypsin complexes and plasmin-ccz-antiplasmin (PAP) com- 
plexes was coUected  in siliconized  vacutainer tubes (Becton Dick- 
inson, Plymouth, UK) to which 0.05% wt/vol hexadimethrine 
bromide (Polybrene;  Janssen Chimica, Beerse, Belgium)  and 10 mM 
EDTA were added to prevent in vitro complex formation. The 
plasma concentration of ehstase-c~l-antitrypsin  and PAP complexes 
1Abbreviations used in  this paper: CLB, Central Laboratory of  the 
Netherlands Red Cross Blood  Transfusion  Service; MFI, mean  fluorescence 
intensity; PAP, plasmin-cx2-antiplasmin; sTNFR, soluble receptor for 
TNF; TAT, thrombin-antithrombin  complex. 
1254  Anti-Ib6  in Endotoxemia 
were measured with R/As (18, 19). Blood (9 vol) for the measure- 
ment  of  the  prothrombin  fragment  F1+2  and  thrombin- 
antithrombin III (TAT) complexes was collected in syringes con- 
taining 3.2% sodium citrate (1 vol). The plasma levels of F1+2 
and TAT complexes  were determined with ELISAs (Behringwerke 
AG, Marburg, Germany). 
In Vitro Tissue Factor  Expression on Monocytes.  To study the role 
of Ib6 on the induction of tissue factor expression on monocytes, 
(heparinized) whole blood from human volunteers was incubated 
in vitro with endotoxin (lot EC-5 from E. coli 0113, 1 or 10 ng/ml) 
in the presence or absence of anti-IL-6 mAb (CLB.IL-6/#8, 30 
/zg/ml). After the incubation, erythrocytes were lysed and leuco- 
cytes were pelleted  and subsequently  washed. Aliquots of  cells were 
incubated with 10/~g/ml antitissue factor mAbs, kindly provided 
by Dr. T. Edgington, Scripps Research Institute, La Jolla, CA) or 
control IgG1 mAb (Becton  Dickinson Immunocytometry Systems, 
San Jose, CA). After washing, the calls were incubated with goat 
anti-mouse Ig antibody conjugated to PE (DAKO, Glostrup, Den- 
mark). The expression of tissue factor was analyzed by immuno- 
cytometry  using a FACScan  |  (Becton  Dickinson Immunocytometry 
Systems) (20). Tissue  factor expression  on monocytes  was expressed 
as the increment in mean fluorescent intensity (MFI) as compared 
with the IgG1 controls. Mean values (and SD) of six experiments 
in each group are given. 
StatisticalAnalysis.  AH values  are give  as means _+ SEM. Changes 
within and differences  between the two treatment groups were 
tested by analysis  of variance, p-values below 0.05 were considered 
statistically significant. 
Results 
IL-6 and Anti-IL-6.  In the chimpanzees treated with en- 
dotoxin alone, a transient rise in serum IL-6 concentrations 
was observed, peaking after 2 h (165  _+  54 pg/ml; p <0.05; 
Fig.  1). Administration of anti-IL-6 mAb CLB.IL-6/#8 led 
to relatively stable serum levels of the mAb throughout the 
5-h experiment (8.4  _+  0.4 #g/m1 after 5 rain;  7.6  _+  0.7 
#g/ml after I h; and 7.4 +  1.2 #g/m1 after 5 h). In the animals 
treated with CLB.IL-6/#8, the initial increase in IL-6 levels 
as measured by ELISA was similar to that recorded in the 
chimpanzees injected with endotoxin alone (Fig.  1). How- 
ever, IL-6 did not decrease towards the end of the experi- 
ment. Peak IL-6 levels were found after 4 h  (1357  _+  298 
pg/ml; p  <0.05 versus endotoxin alone).  These high con- 
centrations were most likely due to impaired clearance of IL-6 
complexed with CLB.IL-6/#8 (21), since in the B9 bioassay 
a corresponding high degree of IL-6 activity could be de- 
tected after addition of an excess (10 #g/ml)  of the non- 
neutralizing anti-IL-6 mAb CLB.IL-6/#14, causing IL-6 to 
dissociate from the in vivo-administered neutralizing mAb 
CLB.IL-6/#8 (1810  _+  499 pg/ml after 5 h; Fig.  1). 
Other Cytokines.  Endotoxin-induced marked increases in 
the serum concentrations of TNF, both types of sTNFKs, 
and IL-8 (Figs. 2 and 3). Peak levels of TNF and its soluble 
receptors were measured after 1.5 h (TNF, 285  _+  75 pg/ml; 
sTNFR type I, 2.8  _+  0.5 ng/ml; sTNFR type II, 6.5  _+ 
1.1 ng/ml; all p <0.05). Maximal IL-8 concentrations were 
found after 3 h  (294  _+  161 pg/ml; p  <0.05). 
The simultaneous injection of anti-IL-6 did not affect these 
endotoxin-induced responses  (Figs.  2 and 3).  Peak concen- 2O0O 
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Figure  1.  Mean  (-- SEM) serum concentrations of immunoreactive  IL-6 
after a bolus intravenous injection of E. coli endotoxin (4 ng/kg) with 
(squares; n =  4) or without (circles; n =  4) a simultaneous bolus intrave- 
nous injection of the neutralizing anti-IL-6 mAb CLB IL-6/#8 (30 rag). 
p-value indicates the difference  between the two treatment groups. Curve 
with triangles indicates IL-6 activity in the chimpanzees treated with CLB 
IL-6/#8 as measured in a modified B9 assay, i.e., in which an excess (10 
/xg/ml) of the nonneutralizing anti-IL-6 mAb CLB IL-6/#14 was added 
to dissociate mAb CLB.IL-6/#8 from IL-6. 
trations of TNF were 181  _+  17 pg/ml (p  =  0.21 versus en- 
dotoxin alone),  of sTNFR  type 1,  2.5  _+  0.3  ng/ml  (p  = 
0.55 versus endotoxin alone), of sTNFR type II, 5.8  -+  0.7 
ng/ml  (p  =  0.71  versus  endotoxin  alone),  and  of  IL-8, 
203  _+  84  ng/ml  (p  =  0.29 versus endotoxin  alone).  The 
fact that  the mean levels of TNF  and IL-8 were higher  in 
the chimpanzees  treated  with  endotoxin  alone was caused 
by one animal in this group that showed very high cytokine 
levels compared with  all other  chimpanzees  studied. 
Neutrophil  Counts  and Degranulation.  Neutrophil  counts 
and  the  plasma  concentrations  of  elastase-ott-antitrypsin 
complexes, indicative of degranulation of neutrophils, are given 
in Fig. 4. Endotoxin elicited a profound leukocytosis, reaching 
a summit at the end of the observation period (from 7.5  _ 
0.4 to 26.7  _+  1.0  x  109/liter; p  <0.05),  which was the re- 
sult  of a marked neutrophilia  (from 4.4  +  0.2  to 24.6  _+ 
1.0  x  109/liter after 5 h; p  <0.05).  In addition,  endotoxin 
provoked  a  rise  in  elastase-otl-antitrypsin  complexes  from 
10.8  _+  4.0 to 20.3  _+  5.3 ng/ml after 5 h  (p <0.05).  None 
of these responses was significantly affected by administra- 
tion  of anti-IL-6. 
Coagulation  and  Fibrinolysis.  Endotoxin  administration 
resulted in an activation of the common pathway of coagula- 
tion, as reflected by rises in the plasma levels of the prothrombin 
fragment FI+ 2 and TAT complexes (Fig. 5). FI+ 2 increased 
from 0.77  _+  0.24  to 4.75  +  1.43  nmol/liter  after 4  h  (p 
<0.05), and TAT complexes increased from 8.6  _+  2.1 to 68.8 
_+ 8.9 ng/liter after 4 h (p <0.05). Endotoxin induced a more 
rapid activation of the fibrinolytic system, as indicated by a 
transient  rise in  the  plasma levels of PAP complexes from 
7.9  +  0.6  to  38.2  _+  15.7  nmol/liter  after 3  h  (p <0.05; 
Fig.  5). 
The simultaneous administration of anti-IL-6 markedly at- 
tenuated  the  endotoxin-induced  activation  of coagulation, 
whereas fibrinolytic activation was not affected (Fig. 5). Peak 
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Figure  2.  Mean  (_+ SEM) serum concentrations of TNF and the soluble 
TNF receptors types I and II after a bolus intravenous injection ofE. coli 
endotoxin (4 ng/kg) with (squares; n  =  4) or without (circles; n  =  4) 
a simultaneous bolus intravenous injection of the neutralizing anti-IL-6 
mAb CLB.IL-6/#8 (30 rag). p  =  values indicate difference between the 
two treatment groups. 
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Figure 3.  Mean (_+ SEM) plasma concentrations of IL-8 after a bolus 
intravenous injection of E. coli endotoxin (4 ng/kg) with (squares; n  = 
4) or without (circles; n =  4) a simultaneous bolus injection of anti-IL-6 
mAb CLB.IL-6/#8 (30 mg). p-value indicates the difference between the 
two treatment  groups. 
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Figure  4.  Mean (_+ SEM) nentrophil  counts and plasma concentrations  f 
of elastase-,vl-antitrypsin complexes after a bolus intravenous injection of 
E.  coli endotoxin (4 ng/kg) with (squares;  n  =  4) or without (circles;  n 
=  4) a simultaneous bolus intravenous injection of anti-IL-6  mAb CLB.IL-  |  =~h,aat~  "t  "[  I  /  6/#8  (30 mg). p-values indicate the difference between the two treatment  lo F 
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plasma levels of Fl+2 and TAT complexes were found after 
5 h (1.13 _  0.13 nmol/liter and 20.3  _+  1.7 ng/liter, respec- 
tively; both p <0.05 versus endotoxin alone). Maximal con- 
centrations of PAP complexes were detected after 2 h (42.3 
_+  11.6 nmol/liter; p  =  0.37 versus endotoxin alone). 
Platelet counts did not change in either group (data not 
shown). 
In Vitro Tissue Factor Expression on Monocytes.  Incubation 
of whole blood with endotoxin (1 or 10 ng/ml) resulted in 
a significant  tissue factor expression  on monocytes (mean MFI, 
8.6 [SD 0.7] and mean MFI, 17.2 [SD 2.3] after 1 and 10 
ng/ml endotoxin, respectively). Endotoxin-induced tissue 
factor expression on monocytes appeared not to be inhibited 
by anti-IL-6 mAbs. The mean MFI after 1 ng/ml endotoxin 
plus  anti-IL-6  mAb (30  #g/ml)  was  10.5 (SD  1.5) (not 
significant as compared with 1 ng/ml endotoxin alone), and 
the mean MFI after 10 ng/ml endotoxin plus anti-IL-6 mAbs 
(30 #g/ml) was 16.4 (SD 3.4) (not significant as compared 
with 10 ng/ml endotoxin alone). 
Discussion 
Sepsis leads to the activation of a series of host mediator 
systems, including the cytokine network, neutrophils,  and 
the hemostatic  mechanism, each of which may contribute 
to the eventual tissue injury and organ damage. This study 
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Figure  5.  Mean (_+ SEM) plasma concentrations ofF1+2, thrombin- 
antithrombin III complexes, and plasmin-c~2-antiplasmin  complexes after 
a bolus intravenous injection ofE. coli endotoxin (4 ng/kg) with (squares; 
n = 4) or without (circles;  n  =  4) a simultaneous bolus intravenous injec- 
tion of anti-Ib6 mAb CLB.Ib6/#8 (30 mg)./,-values indicate the differ- 
ence between the two treatment groups. 
aimed to assess the role of IL-6 in the early phases of this 
sepsis cascade. It was demonstrated that treatment with anti- 
IL-6 mAb in low grade endotoxemia in chimpanzees did not 
affect cytokine and leukocyte responses, whereas this inter- 
vention strongly inhibited coagulation  activation. 
Endotoxin-induced IL-6 activity was neutralized by the 
simultaneous administration  of the anti-IL-6 mAb CLB.IL- 
6/#8 (10), of which stable high serum levels were achieved 
throughout the experiment. Immunoreactive IL-6 was higher 
in the animals treated with CLB.IL-6/#8,  because of the for- 
mation of IL-6-mAb complexes that have a far longer serum 
half-life than free IL-6. IL-6 activity was effectively blocked 
in the chimpanzees treated with CLB.IL-6/#8,  considering 
the large excess  of antibody that was injected compared with 
the amount of IL-6 produced and the potency of the anti- 
body to neutralize IL-6 activity in vitro (10). Based on the 
mAb concentrations achieved in serum (',~5 x  10 -8 M) and 
the affinity of the mAb (6  x  10-t2 M) (10), the expected 
ratio of bound over free ILo6 is about 5,000. In view of the 
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of IL-6 was free in the animals treated with the anti-IL-6 mAb. 
IL-6 may have opposite effects on TNF production and 
TNF activity. IL-6 suppresses  endotoxin-induced TNF produc- 
tion by mononudear cells in vitro, and in intact mice in vivo 
(8, 9). On the other hand, IL-6 can upregulate TNF receptors 
on several cell types, and potentiate the cytotoxic effect of 
TNF on U937 cells (22, 23). The extracellnlar  domains of 
both known types of TNF receptors also exist in soluble forms 
in the extracellular  milieu (24). These sTNFKs types I and 
II compete with the cell-bound TNF receptors for the binding 
of free TNF, and are considered important regulators of the 
bioavailability of this cytokine. The serum levels of ffNFtLs 
are elevated in clinical and experimental sepsis, in which they 
may serve as a self-defense mechanism against excessive TNF 
activity (15, 16, 25). Our results demonstrate that endoge- 
nous IL-6 does not affect TNF production, or the shedding 
of TNF receptors,  after a single injection of a low dose of 
endotoxin. The same  is  true for  endotoxin-induced IL-8 
production, to which, considering the unchanged IL-8 re- 
sponse in the presence of anti-IL-6, IL-6 does not seem to 
contribute. 
Endotoxin administration was associated with a pronounced 
neutrophilic lenkocytosis. Although IL-6 is capable of inducing 
neutrophilia in several species (7, 26), treatment with anti- 
IL-6 mAb did not influence this response,  suggesting that 
other factors such as endotoxin itself, TNF, and/or IL-8 are 
responsible (27, 28). Neutrophil activation is thought to con- 
tribute to tissue damage in sepsis. Indeed, markers ofneutro- 
phil degranulation are elevated in the plasma of patients with 
sepsis, and correlate  with mortality rates (18). Elastase is a 
highly potent proteinase derived from azurophilic granules 
of neutrophils, that circulates in complex with its inhibitor 
ctl-antitrypsin.  In accordance with previous reports (11, 29), 
endotoxin provoked a transient rise in the plasma concentra- 
tions of elastase-c~l-antitrypsin complexes. Injection of anti- 
IL-6 did not prevent this increase, suggesting that, although 
IL-6 may cause degranulation of neutrophils in vitro (30), 
the cytokine is not of great importance in this endotoxin- 
induced response in vivo. Likely, TNF is more significant 
for neutrophil degranulation in endotoxemia, because TNF 
potently elicits neutrophil degranulation in healthy humans 
(27), and inhibition of TNF synthesis after injection of en- 
dotoxin by pentoxifylline strongly reduced the increase in 
elastase-ol~-antitrypsin complexes in this chimpanzee model 
(11). In addition, IL-8 may play a role,  since this cytokine 
is an important stimulator of neutrophil functions, especially 
after priming with TNF (31, 32). 
Disseminated intravascular coagulation is a major compli- 
cation of sepsis. Our previous studies in humans and chim- 
panzees have demonstrated that endotoxin provokes a sus- 
tained activation of the coagulation system via the extrinsic 
tissue factor-mediated pathway, preceded by a transient acti- 
vation of the fibrinolytic system (33-35). In this study anti- 
IL-6 inhibited endotoxin-induced activation of the coagula- 
tion system. The mechanism by which the antibody achieved 
this effect remains to be established. Although anti-IL-6 did 
not affect the induction of tissue factor on mononuclear cells 
stimulated by endotoxin in vitro, this does not absolutely 
rule out that IL-6 has an effect on tissue factor expression 
by monocytes in vivo, or a stimulatory role of IL-6 on tissue 
factor expression by endothelial cells. Indeed, baboons infused 
with IL-6 showed enhanced expression of tissue factor by cir- 
culating monocytes (Taylor, Fletcher B., personal communi- 
cation), whereas very recently, our group found rises in the 
plasma concentrations of FI+ 2 and TAT complexes after in- 
fusion of IL-6 into cancer patients (Stouthard, Jacqueline M., 
et al., manuscript in preparation). Furthermore, in sepsis, IL-6 
may contribute to coagulation activation indirectly by induc- 
tion of C-reactive protein, which in turn is able to stimulate 
tissue factor production (36). Of interest, reciprocal interac- 
tions may exist between IL-6 and the extrinsic pathway of 
the coagulation system, since treatment of septic baboons with 
tissue factor pathway inhibitor (TFPI) has shown to reduce 
not only the coagulative response, but also IL-6 plasma con- 
centrations (37). Therefore, another explanation for the in- 
hibitory effect of anti-IL-6 treatment on endotoxin-induced 
coagulation activation might be that anti-IL-6 induces alter- 
ations in natural anticoagulant functions such as TFPI, but 
possibly also other coagulation protease inhibitors such as 
protein C. 
Administration of anti-lL-6 did not affect the early fibrino- 
lytic activation after injection of endotoxin, confirming our 
previous finding that the stimulation of fibrinolysis and coagu- 
lation proceeds independently  in low grade endotoxemia (34, 
35). Intervention with an anti-TNF mAb in this model has 
implicated TNF  as  an  important  intermediate factor  in 
endotoxin-induced  activation of the fibrinolytic system (38). 
In conclusion, our study indicates that IL-6 produced in 
response to a bolus dose of endotoxin, has no major feedback 
effect on the ongoing activation of the cytokine network, 
and that it is not involved in the ensuing neutrophilia and 
neutrophil degranulation. In this model of low grade endotox- 
emia, IL-6 appears to be a pivotal factor, most likely in an 
indirect way, for coagulation activation. This may explain 
why treatment with anti-IL-6 mAb has been found to pro- 
vide significant protection against mortality in the general- 
ized Shwartzman reaction, and some protection in lethal en- 
dotoxemia in mice (5, 6). Further studies are needed to assess 
the role of IL-6 after more severe bacterial  challenges. 
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